![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
Under the partnership, Synaptogenix obtains a preemptive right to fund the further research and commercialization of certain intellectual property, technology, and for cannabinoid- and psilocybin mushroom-based therapeutics for multiple indications.
Lead Product(s): Cannabinoid-based Therapeutic
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Synaptogenix
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Partnership November 02, 2023